Hollsteen
← Astera Labs

Equity incl. NCI

Balance – as of period end · $M

QuartersFiscal years

$MEquity incl. NCI · Q1 2016: missing – No verified SEC value extracted, although the company reports this metric in other periods.Equity incl. NCI · Q2 2016: missing – No verified SEC value extracted, although the company reports this metric in other periods.Equity incl. NCI · Q3 2016: missing – No verified SEC value extracted, although the company reports this metric in other periods.Equity incl. NCI · Q4 2016: missing – No verified SEC value extracted, although the company reports this metric in other periods.Equity incl. NCI · Q1 2017: missing – No verified SEC value extracted, although the company reports this metric in other periods.Equity incl. NCI · Q2 2017: missing – No verified SEC value extracted, although the company reports this metric in other periods.Equity incl. NCI · Q3 2017: missing – No verified SEC value extracted, although the company reports this metric in other periods.Equity incl. NCI · Q4 2017: missing – No verified SEC value extracted, although the company reports this metric in other periods.Equity incl. NCI · Q1 2018: missing – No verified SEC value extracted, although the company reports this metric in other periods.Equity incl. NCI · Q2 2018: missing – No verified SEC value extracted, although the company reports this metric in other periods.Equity incl. NCI · Q3 2018: missing – No verified SEC value extracted, although the company reports this metric in other periods.Equity incl. NCI · Q4 2018: missing – No verified SEC value extracted, although the company reports this metric in other periods.Equity incl. NCI · Q1 2019: missing – No verified SEC value extracted, although the company reports this metric in other periods.Equity incl. NCI · Q2 2019: missing – No verified SEC value extracted, although the company reports this metric in other periods.Equity incl. NCI · Q3 2019: missing – No verified SEC value extracted, although the company reports this metric in other periods.Equity incl. NCI · Q4 2019: missing – No verified SEC value extracted, although the company reports this metric in other periods.Equity incl. NCI · Q1 2020: missing – No verified SEC value extracted, although the company reports this metric in other periods.Equity incl. NCI · Q2 2020: missing – No verified SEC value extracted, although the company reports this metric in other periods.Equity incl. NCI · Q3 2020: missing – No verified SEC value extracted, although the company reports this metric in other periods.Equity incl. NCI · Q4 2020: missing – No verified SEC value extracted, although the company reports this metric in other periods.Equity incl. NCI · Q1 2021: missing – No verified SEC value extracted, although the company reports this metric in other periods.Equity incl. NCI · Q2 2021: missing – No verified SEC value extracted, although the company reports this metric in other periods.Equity incl. NCI · Q3 2021: missing – No verified SEC value extracted, although the company reports this metric in other periods.Equity incl. NCI · Q4 2021: −$40.0M · 10-K 0001736297-25-000003 filed Feb 14, 2025Equity incl. NCI · Q1 2022: missing – No verified SEC value extracted, although the company reports this metric in other periods.Equity incl. NCI · Q2 2022: missing – No verified SEC value extracted, although the company reports this metric in other periods.Equity incl. NCI · Q3 2022: missing – No verified SEC value extracted, although the company reports this metric in other periods.Equity incl. NCI · Q4 2022: −$85.0M · 10-K 0001736297-25-000003 filed Feb 14, 2025Equity incl. NCI · Q1 2023: −$100M · 10-Q 0001736297-24-000006 filed May 8, 2024Equity incl. NCI · Q2 2023: −$117M · 10-Q 0001736297-24-000018 filed Aug 7, 2024Equity incl. NCI · Q3 2023: −$117M · 10-Q 0001736297-24-000043 filed Nov 5, 2024Equity incl. NCI · Q4 2023: −$98.0M · 10-K 0001736297-25-000003 filed Feb 14, 2025Equity incl. NCI · Q1 2024: $809M · 10-Q 0001736297-24-000006 filed May 8, 2024Equity incl. NCI · Q2 2024: $845M · 10-Q 0001736297-24-000018 filed Aug 7, 2024Equity incl. NCI · Q3 2024: $890M · 10-Q 0001736297-24-000043 filed Nov 5, 2024Equity incl. NCI · Q4 2024: $965M · 10-K 0001736297-25-000003 filed Feb 14, 2025Equity incl. NCI · Q1 2025: $1.0B · 10-Q 0001736297-25-000031 filed May 7, 2025Equity incl. NCI · Q2 2025: $1.1B · 10-Q 0001736297-25-000098 filed Aug 6, 2025Equity incl. NCI · Q3 2025: $1.3B · 10-Q 0001736297-25-000147 filed Nov 5, 2025Equity incl. NCI · Q4 2025: $1.4B · 10-K 0001736297-26-000010 filed Feb 20, 2026Equity incl. NCI · Q1 2026: $1.5B · 10-Q 0001736297-26-000020 filed May 6, 2026Equity incl. NCI · Q2 2026: $1.7B · 10-Q 0001736297-26-000035 filed Aug 5, 2026missing−851,726−40Q1 2016Q2 2026Q4 2022
$MEquity incl. NCI · Q4 2021: −$40.0M · 10-K 0001736297-25-000003 filed Feb 14, 2025Equity incl. NCI · Q1 2022: missing – No verified SEC value extracted, although the company reports this metric in other periods.Equity incl. NCI · Q2 2022: missing – No verified SEC value extracted, although the company reports this metric in other periods.Equity incl. NCI · Q3 2022: missing – No verified SEC value extracted, although the company reports this metric in other periods.Equity incl. NCI · Q4 2022: −$85.0M · 10-K 0001736297-25-000003 filed Feb 14, 2025Equity incl. NCI · Q1 2023: −$100M · 10-Q 0001736297-24-000006 filed May 8, 2024Equity incl. NCI · Q2 2023: −$117M · 10-Q 0001736297-24-000018 filed Aug 7, 2024Equity incl. NCI · Q3 2023: −$117M · 10-Q 0001736297-24-000043 filed Nov 5, 2024missing−85−117−40Q4 2021Q3 2023Q4 2022
Q4 2022
−85$M
All values (16)
PeriodValue ($M)Status
Q2 20261,726reported
Q1 20261,494reported
Q4 20251,364reported
Q3 20251,272reported
Q2 20251,136reported
Q1 20251,042reported
Q4 2024965reported
Q3 2024890reported
Q2 2024845reported
Q1 2024809reported
Q4 2023−98reported
Q3 2023−117reported
Q2 2023−117reported
Q1 2023−100reported
Q4 2022−85reported
Q4 2021Noneerror

26 periods without value hidden · Show gaps with reason · CSV with all sources · Technical ID: equity_total

More metrics for Astera Labs

Income statement

Per share

Balance sheet

Cash flow

Revenue by segment/product/region

Sources & calculation
Value
−$85.0M
Period
Q4 2022, ended Dec 31, 2022 · as of Dec 31, 2022 (balance as of date, not a sum)
Source
10-K, filed Feb 14, 2025 · 0001736297-25-000003
Location
us-gaap:StockholdersEquity
Confidence
1. – directly from an XBRL fact in the filing (or calculated exactly from it)

Versions

v1−$85.0MFeb 14, 202510-K 0001736297-25-000003reported · confidence 1. · current